Stock ZURA ZURA BIO LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Real-time Estimate Cboe BZX
Other stock markets
 11:36:45 2024-06-05 EDT 		5-day change 1st Jan Change
4.56 USD +2.24% Intraday chart for Zura Bio Limited -15.05% -4.50%
06-03 Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 CI
05-23 Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
BU
Zura Bio Limited to Present Data Exploring the Expanded Potential of Tibulizumab Into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
CI
Zura Bio Announces Participation in June Investor Conferences
BU
Zura Bio Insider Bought Shares Worth $496,000, According to a Recent SEC Filing
MT
Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating
MT
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
BU
Zura Bio Limited announced that it has received $112.4935 million in funding from a group of investors
CI
Piper Sandler Starts Zura Bio With Overweight Rating, $26 Price Target
MT
Zura Bio Insider Bought Shares Worth $499,999, According to a Recent SEC Filing
MT
Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing
MT
Zura Bio Expects To Raise About $112.5 Million in Gross Proceeds From Oversubscribed Private Placement
MT
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
BU
Zura Bio Limited announced that it expects to receive $112.4935 million in funding from a group of investors
CI
Sector Update: Health Care Stocks Softer Monday Afternoon
MT
Zura Bio Shares Rise After Robert Lisicki Assumes CEO Role
MT
Zura Bio Announces Robert Lisicki as CEO and Director
BU
Oppenheimer Adjusts Zura Bio Price Target to $16 From $17, Maintains Outperform Rating
MT
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
BU
Zura Bio Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZURA Stock
  4. News Zura Bio Limited